Published in: Genetic Engineering News
On: November 13, 1999
“Last month, Genentech, Inc. (S. San Francisco) and Alkermes, Inc. (Cambridge, MA) reported positive results of their Phase III multi-center trial of Nutopin Depot, the first long-acting form of recombinant growth hormone. The two companies jointly presented findings at the Endocrine Society annual meeting in San Diego that showed Nutropin Deopt increased growth rates in children with growth hormone deficiency.”
